INDIANAPOLIS, IN, USA (Press Release) - May 30, 2009
Your session will expire in 8 hours requiring you to log in each day to view content.
Browse Categories
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Your session will expire in 8 hours requiring you to log in each day to view content.